|1.||Anderson, Kenneth C: 129 articles (04/2015 - 05/2002)|
|2.||Richardson, Paul G: 106 articles (01/2016 - 09/2002)|
|3.||Hideshima, Teru: 65 articles (04/2014 - 05/2002)|
|4.||Palumbo, Antonio: 58 articles (09/2015 - 03/2006)|
|5.||Orlowski, Robert Z: 57 articles (12/2015 - 11/2002)|
|6.||Sonneveld, Pieter: 48 articles (09/2015 - 06/2005)|
|7.||Lonial, Sagar: 46 articles (01/2016 - 06/2005)|
|8.||Chauhan, Dharminder: 45 articles (04/2014 - 05/2002)|
|9.||Bladé, Joan: 42 articles (08/2015 - 01/2005)|
|10.||van de Velde, Helgi: 41 articles (11/2015 - 02/2006)|
10/01/2007 - "In the Japanese phase I/II study of bortezomib for relapsed multiple myeloma, this agent showed remarkable efficacy, with acceptable toxicities and unique pharmacokinetic/pharmacodynamic profiles, warranting further investigations, including more relevant administration schedules."
04/01/2010 - "Bortezomib is highly effective in multiple myeloma and is widely used in this disease. "
01/01/2014 - "We have developed several other important use cases; as an example, we have shown that prediction of bortezomib sensitivity in multiple myeloma may be improved by training models on a large set of neoplastic hematological cell lines. "
01/01/2009 - "We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. "
08/01/2007 - "Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. "
09/01/2000 - "Taken together, the results indicate that unlike most other known anticancer cytotoxic drugs, PS-341 appears to be as effective in killing tumor cells grown in the form of multicell spheroids as in killing tumor cells grown in monolayer cell culture. "
01/01/2014 - "Bortezomib-based regimens were more effective in reducing tumor burden and achieving therapeutic (complete and partial) response compared with non-bortezomib-based regimens irrespective of Bcl-2 or survivin expression (P < 0.05). "
12/01/2005 - "After three cycles of bortezomib, the patient achieved near-complete remission, as well as a nearly complete regression of the paravertebral tumor. "
03/01/2014 - "At the same time points, the combination therapy produced ~75 and ~84% decreases in tumor growth, respectively, which were significantly greater than the reduction produced by bortezomib monotherapy. "
12/28/2012 - "Targeting the ubiquitin+proteasome protein degradation pathway with the therapeutic agent bortezomib has significantly improved the survival of cancer patients but drug resistance inevitably develops. "
|3.||Peripheral Nervous System Diseases (PNS Diseases)
09/01/2014 - "To examine the safety, feasibility and efficacy of acupuncture in reducing bortezomib-induced peripheral neuropathy (BIPN) symptoms. "
05/01/2014 - "Subcutaneous administration of bortezomib offers similar efficacy to standard intravenous administration in the treatment of multiple myelom, with an improved safety for lower rate of peripheral neuropathy."
02/01/2012 - "The incorporation of bortezomib as a consolidation therapy improved the clinical outcome with the expense of rather frequent development of peripheral neuropathy."
09/01/2015 - "The relative risks of bortezomib-induced peripheral neuropathy compared to placebo were increased for all-grade (RR = 4.89; 95 % CI, 2.52-9.51) and high-grade (RR = 4.53; 95 % CI, 2.04-10.07) peripheral neuropathy (for randomized controlled trials only). "
11/01/2014 - "In this study we have investigated the role played by subtype 5 of metabotropic receptors in bortezomib induced peripheral neuropathy. "
|4.||Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
11/01/2015 - "Although most of the mantle cell lymphoma (MCL) patients initially responded well to bortezomib (BTZ), the dose-dependent toxicities have greatly limited the application of BTZ to MCL. "
01/01/2008 - "Single-agent bortezomib is effective in several lymphoid malignancies, and is recommended for second-line treatment of mantle-cell lymphoma (MCL). "
11/10/2015 - "Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance."
02/01/2005 - "Encouraging activity has been demonstrated with bortezomib in the first-line treatment of myeloma and in patients with mantle cell lymphoma. "
04/01/2009 - "The recent approval of bortezomib for the treatment of mantle cell lymphoma (MCL) by the US Food and Drug Administration is based on the results of the multicentre PINNACLE study with supportive data from a number of single and multicentre Phase 2 studies. "
02/01/2008 - "Bortezomib shows promise in the treatment of systemic AL amyloidosis."
02/01/2008 - "Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease."
07/01/2015 - "Recent studies support the use of bortezomib-based therapies in light chain amyloidosis (AL). "
10/16/2014 - "Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis."
06/07/2012 - "The results of the present study show that RdC is an oral regimen with activity in primary systemic light chain amyloidosis and may be an additional treatment option, especially for patients with preserved organ function or for patients who cannot receive or who relapse after bortezomib. "
|1.||Proteasome Endopeptidase Complex (Proteasome)
|3.||lenalidomide (CC 5013)
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Hematopoietic Stem Cell Transplantation